Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
The hypothesis that induction avelumab could enhance the efficacy of subsequent ChT was not proven. Administering IO alone as induction before ChT is not an adequate strategy.
Authors
- Marta Doménech (ORCID: https://orcid.org/0000-0003-4827-9170)
- Óscar Juan (ORCID: https://orcid.org/0000-0002-7772-9030)
- Begoña Mellado (ORCID: https://orcid.org/0000-0002-8088-5966)
- Teresa Bonfill (ORCID: https://orcid.org/0000-0003-2775-0293)
- Daniel Castellano (ORCID: https://orcid.org/0000-0002-9106-0687)
- Enrique González‐Billalabeitia (ORCID: https://orcid.org/0000-0003-3143-3143)
- Pablo Maroto (ORCID: https://orcid.org/0000-0002-0030-0412)
- José Luis Perez‐Gracia (ORCID: https://orcid.org/0000-0003-4941-9075)
- Begoña P. Valderrama (ORCID: https://orcid.org/0000-0003-0175-1263)
- Xavier García del Muro (ORCID: https://orcid.org/0000-0001-5571-2847)
- Federico Vázquez (ORCID: https://orcid.org/0000-0001-6493-2374)
- Rafael Morales‐Barrera (ORCID: https://orcid.org/0000-0001-7398-0685)
- J. Puente
- Joaquim Bellmunt (ORCID: https://orcid.org/0000-0003-2328-3421)
- N. Navarro-Gorro
- Álvaro Pinto (ORCID: https://orcid.org/0000-0002-4719-053X)
- Alejo Rodríguez‐Vida (ORCID: https://orcid.org/0000-0002-7304-6857)
- Núria Juanpere (ORCID: https://orcid.org/0000-0003-4954-9494)
- M.Á. Climent
Institutions
- Boston University (US)
- Hebron University (PS)
- Universitat Autònoma de Barcelona (ES)
- Harvard University (US)
- Hospital Universitario La Paz (ES)
- Hospital de Sant Pau (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Pivotal (Spain) (ES)
- Hospital General Universitario Morales Meseguer (ES)
- Althaia (ES)
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES)
- Fundación Instituto Valenciano de Oncología (ES)
- Clinical Research Organization (BD)
- Institut Català d'Oncologia (ES)
- Hospital General Universitario de Elche (ES)
- Dana-Farber Cancer Institute (US)
- Hospital Del Mar (ES)
- Dana-Farber/Harvard Cancer Center (US)
- Clinica Universidad de Navarra (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103690
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Astellas Pharma US
- AstraZeneca
- Merck
- Roche
- Sanofi
- Gilead Sciences
- Les Laboratories Pierre Fabre
- Incyte
- Eisai
- Astellas Pharma
- Ipsen
- EUSA Pharma
- Cilag